Efeito da talidomida sobre os níveis séricos de imunoglobulinas IgM e IgA, fator reumatóide e isohemaglutinina anti-A e anti-B em pacientes com lepra lepromatosa: um estudo duplo-cego

Arruda, Walter Oleschko; Hacbarth, Elisa; Döi, Elvira; Santa-Maria, Jesus R.; Barbosa, Jânio; Kajdacsy-Balla, André A.

doi:10.1590/S0036-46651986000100003

Resumos

Um estudo duplo-cego foi conduzido em pacientes portadores de lepra lepromatosa estável, para avaliar a resposta à administração de talidomida 100 mg por dia, por 18 dias, dos níveis séricos de IgM e IgA e dos títulos de fator reumatóide e isohemaglutininas anti-A e anti-B. Nenhum efeito significativo foi detectado ao fim deste período.

Hanseníase Virchowiana; Sorologia; Imunoglobulinas IgM e IgA; Fator reumatóide; Isohemaglutininas Anti-A e Anti-B; Talidomida

A double-blind study was performed in a group of patients with lepromatous leprosy to evaluate the response of IgM and IgA serum levels and of serum titles of rheumatoid factor and isohemaglutinins anti-A and anti-B to administration of thalidomide 100 mg each day, for 18 days. No significant effect was detected at the end of the study.

ARTIGOS ORIGINAIS

Efeito da talidomida sobre os níveis séricos de imunoglobulinas IgM e IgA, fator reumatóide e isohemaglutinina anti-A e anti-B em pacientes com lepra lepromatosa. Um estudo duplo-cego

Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemaglutinins anti-A and anti-B in patients with lepromatous leprosy. A double-blind study

Walter Oleschko Arruda^I; Elisa Hacbarth^I; Elvira Döi^I; Jesus R. Santa-Maria^II; Jânio Barbosa^I; André A. Kajdacsy-Balla^I

^ILaboratório de Imunopatologia, Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, PR, Brasil

^IIHospital Dermatológico-Sanitário São Roque, Fundação Caetano Munhoz da Rocha, Piraquara. PR, Brasil

RESUMO

Um estudo duplo-cego foi conduzido em pacientes portadores de lepra lepromatosa estável, para avaliar a resposta à administração de talidomida 100 mg por dia, por 18 dias, dos níveis séricos de IgM e IgA e dos títulos de fator reumatóide e isohemaglutininas anti-A e anti-B. Nenhum efeito significativo foi detectado ao fim deste período.

Unitermos: Hanseníase Virchowiana Sorologia Imunoglobulinas IgM e IgA. Fator reumatóide Isohemaglutininas Anti-A e Anti-B Talidomida

SUMMARY

A double-blind study was performed in a group of patients with lepromatous leprosy to evaluate the response of IgM and IgA serum levels and of serum titles of rheumatoid factor and isohemaglutinins anti-A and anti-B to administration of thalidomide 100 mg each day, for 18 days.

No significant effect was detected at the end of the study.

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

Recebido para publicação em 15/10/1984.

1 ANDERSON. R.; GATNEE, E. M. S.; van RENSBURG, C. E.; GRABOW, G.; IMKAMP, F. M. G. H.; KOK. S. K. & van RENSBURG, J. In vitro and In vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob. Agents Chemother. 19: 495-503, 1981.
2. BARNHILL, R. L. & McDOUGALL, A. C. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J. Am. Acad. Dermatol. 7: 317 323, 1982.
3. BJUNE, G.; CLOSS, O. & BARNETSON, R. ST. C. Early events in the host-parasite relationship and immune, response in clinical leprosy: its importance for leprosy control. Clin. Exp. Immunol. 54: 289-297, 1983.
4. BULLOCK, W. E.; WATSON, S.; NELSON, K. E.; SHAUF, V. I.; MAKONKAWEYON, S. & JACOBSON, R. R. Aberrant immunoregulatory control of B lymphocyte function in lepromatous leprosy. Clin. Exp. Immunol. 49: 105-114, 1982.
5. CATHCART, E. S.; WILLIAMS, Jr., R. C; ROSS, S. H. & CALKINS. E. - The relationship of the latex fixation test to the clinical and serologic manifestations of leprosy. Am. J. Med. 31: 758-765, 1961.
6. DACIE, J. V. & LEWIS, S. M. Hematología Práctica 2.ed. Barcelona, Toray, 1970, Cap. 15, p. 427.
7. ELLIS, B. P. B. Leprosy and the rheumatoid factor. Cent. Afr. J. Med. 24: 8-10. 1978.
8. GUSDON, J. P. & COHEN, C. Effect of thalidomide on the antibody response. Am. J. Obst. Gynec. 100: 952-956, 1968.
9. HILL, A. B. Principles of Medical Statistics. 9.ed. New York, Oxford University Press, 1971.
10. INMAN, R. D. & DAY, N. K. Immunologic and clinical aspects of immune complex disease. Am. J. Med. 10: 1097-1106, 1981.
11. MAINI, R. N. - The clinical and pathogenetic significance of rheumatoid factor. Aust. N. Z. J. Med. 8 (Supl. 1); 51-56, 1978.
12. RIDLEY, D. S. & JOPLING, W. H. Classification of leprosy according to immunity. A five group system. Int. J. Lepr. 34: 255-273, 1966.
13. SHANNON, E. J.; MIRANDA, R. O.; MORALES, M. J. & HASTINGS, R. C. Inhibition or de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand. J. Immunol. 13: 553-562, 1981.
14. SIEGEL, S. Estatística Não-paramétrica. São Paulo, McGraw-Hill do Brasil, 1975.
15. WELLS, J. V. Immunoglobulins: biosynthesis and metabolism. In: FUNDENBERG, H. H.; STITES, D. P.; CALDWELL, J. L. & WELLS, J. V. Basic and Clinical Immunology. 3.ed. Los Altos, California, Lange Medical Publications, 1980, Cap. 7A, p. 72.

Datas de Publicação

Publicação nesta coleção
16 Out 2012
Data do Fascículo
Fev 1986

Histórico

Recebido
15 Out 1984

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

[1] 1 ANDERSON. R.; GATNEE, E. M. S.; van RENSBURG, C. E.; GRABOW, G.; IMKAMP, F. M. G. H.; KOK. S. K. & van RENSBURG, J. In vitro and In vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Antimicrob. Agents Chemother. 19: 495-503, 1981.

[2] 2. BARNHILL, R. L. & McDOUGALL, A. C. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J. Am. Acad. Dermatol. 7: 317 323, 1982.

[3] 3. BJUNE, G.; CLOSS, O. & BARNETSON, R. ST. C. Early events in the host-parasite relationship and immune, response in clinical leprosy: its importance for leprosy control. Clin. Exp. Immunol. 54: 289-297, 1983.

[4] 4. BULLOCK, W. E.; WATSON, S.; NELSON, K. E.; SHAUF, V. I.; MAKONKAWEYON, S. & JACOBSON, R. R. Aberrant immunoregulatory control of B lymphocyte function in lepromatous leprosy. Clin. Exp. Immunol. 49: 105-114, 1982.

[5] 5. CATHCART, E. S.; WILLIAMS, Jr., R. C; ROSS, S. H. & CALKINS. E. - The relationship of the latex fixation test to the clinical and serologic manifestations of leprosy. Am. J. Med. 31: 758-765, 1961.

[6] 6. DACIE, J. V. & LEWIS, S. M. Hematología Práctica 2.ed. Barcelona, Toray, 1970, Cap. 15, p. 427.

[7] 7. ELLIS, B. P. B. Leprosy and the rheumatoid factor. Cent. Afr. J. Med. 24: 8-10. 1978.

[8] 8. GUSDON, J. P. & COHEN, C. Effect of thalidomide on the antibody response. Am. J. Obst. Gynec. 100: 952-956, 1968.

[9] 9. HILL, A. B. Principles of Medical Statistics. 9.ed. New York, Oxford University Press, 1971.

[10] 10. INMAN, R. D. & DAY, N. K. Immunologic and clinical aspects of immune complex disease. Am. J. Med. 10: 1097-1106, 1981.

[11] 11. MAINI, R. N. - The clinical and pathogenetic significance of rheumatoid factor. Aust. N. Z. J. Med. 8 (Supl. 1); 51-56, 1978.

[12] 12. RIDLEY, D. S. & JOPLING, W. H. Classification of leprosy according to immunity. A five group system. Int. J. Lepr. 34: 255-273, 1966.

[13] 13. SHANNON, E. J.; MIRANDA, R. O.; MORALES, M. J. & HASTINGS, R. C. Inhibition or de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand. J. Immunol. 13: 553-562, 1981.

[14] 14. SIEGEL, S. Estatística Não-paramétrica. São Paulo, McGraw-Hill do Brasil, 1975.

[15] 15. WELLS, J. V. Immunoglobulins: biosynthesis and metabolism. In: FUNDENBERG, H. H.; STITES, D. P.; CALDWELL, J. L. & WELLS, J. V. Basic and Clinical Immunology. 3.ed. Los Altos, California, Lange Medical Publications, 1980, Cap. 7A, p. 72.

Brasil

Brasil

Efeito da talidomida sobre os níveis séricos de imunoglobulinas IgM e IgA, fator reumatóide e isohemaglutinina anti-A e anti-B em pacientes com lepra lepromatosa: um estudo duplo-cego

Effect of thalidomide on serum levels of immunoglobulins IgM and IgA, rheumatoid factor and isohemaglutinins anti-A and anti-B in patients with lepromatous leprosy: a double-blind study

Resumos

Datas de Publicação

Histórico